SEARCH

SEARCH BY CITATION

References

  • Anderson, J.L., Horne, B.D., Stevens, S.M., Grove, A.S., Barton, S., Nicholas, Z.P., Kahn, S.F., May, H.T., Samuelson, K.M., Muhlestein, J.B. & Carlquist, J.F. (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation, 116, 25632570.
  • Baglin, T.P., Cousins, D., Keeling, D.M., Perry, D.J. & Watson, H.G. (2007) Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. British Journal of Haematology, 136, 2629.
  • Burmester, J.K., Berg, R.L., Yale, S.H., Rottscheit, C.M., Glurich, I.E., Schmelzer, J.R. & Caldwell, M.D. (2011) A randomized controlled trial of genotype-based Coumadin initiation. Genetics in Medicine, 13, 509518.
  • Caldwell, M.D., Berg, R.L., Zhang, K.Q., Glurich, I., Schmelzer, J.R., Yale, S.H., Vidaillet, H.J. & Burmester, J.K. (2007) Evaluation of genetic factors for warfarin dose prediction. Clinical Medicine and Research, 5, 816.
  • Caraco, Y., Blotnick, S. & Muszkat, M. (2008) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clinical Pharmacology and Therapeutics, 83, 460470.
  • Carlquist, J.F. & Anderson, J.L. (2011) Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation, 124, 25542559.
  • Fennerty, A., Dolben, J., Thomas, P., Backhouse, G., Bentley, D.P., Campbell, I.A. & Routledge, P.A. (1984) Flexible induction dose regimen for warfarin and prediction of maintenance dose. British Medical Journal (Clinical Research Ed.), 288, 12681270.
  • Ferder, N.S., Eby, C.S., Deych, E., Harris, J.K., Ridker, P.M., Milligan, P.E., Goldhaber, S.Z., King, C.R., Giri, T., McLeod, H.L., Glynn, R.J. & Gage, B.F. (2010) Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. Journal of Thrombosis and Haemostasis, 8, 95100.
  • Flockhart, D.A., O'Kane, D., Williams, M.S., Watson, M.S., Flockhart, D.A., Gage, B., Gandolfi, R., King, R., Lyon, E., Nussbaum, R., O'Kane, D., Schulman, K., Veenstra, D., Williams, M.S. & Watson, M.S. (2008) Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genetics in Medicine, 10, 139150.
  • Higashi, M.K., Veenstra, D.L., Kondo, L.M., Wittkowsky, A.K., Srinouanprachanh, S.L., Farin, F.M. & Rettie, A.E. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Journal of the American Medical Association, 287, 16901698.
  • Hillman, M.A., Wilke, R.A., Yale, S.H., Vidaillet, H.J., Caldwell, M.D., Glurich, I., Berg, R.L., Schmelzer, J. & Burmester, J.K. (2005) A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clinical Medicine and Research, 3, 137145.
  • Kangelaris, K.N., Bent, S., Nussbaum, R.L., Garcia, D.A. & Tice, J.A. (2009) Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin Journal of General Internal Medicine, 24, 656664.
  • Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., Kitchen, S. & Makris, M. (2011) Guidelines on oral anticoagulation with warfarin – fourth edition. British Journal of Haematology, 154, 311324.
  • Klein, T.E., Altman, R.B., Eriksson, N., Gage, B.F., Kimmel, S.E., Lee, M.T., Limdi, N.A., Page, D., Roden, D.M., Wagner, M.J., Caldwell, M.D. & Johnson, J.A. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. New England Journal of Medicine, 360, 753764.
  • Le Gal, G., Carrier, M., Tierney, S., Majeed, H., Rodger, M. & Wells, P.S. (2010) Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping? Journal of Thrombosis and Haemostasis, 8, 9094.
  • Lenzini, P.A., Grice, G.R., Milligan, P.E., Dowd, M.B., Subherwal, S., Deych, E., Eby, C.S., King, C.R., Porche-Sorbet, R.M., Murphy, C.V., Marchand, R., Millican, E.A., Barrack, R.L., Clohisy, J.C., Kronquist, K., Gatchel, S.K. & Gage, B.F. (2008) Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. Journal of Thrombosis and Haemostasis, 6, 16551662.
  • Mannucci, P.M., Spreafico, M. & & Peyvandi, F. (2008) Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. Journal of Thrombosis and Haemostasis, 6, 14501452.
  • Margaglione, M., Colaizzo, D., D'Andrea, G., Brancaccio, V., Ciampa, A., Grandone, E. & Di Minno, G. (2000) Genetic modulation of oral anticoagulation with warfarin. Thrombosis and Haemostasis, 84, 775778.
  • Millican, E.A., Lenzini, P.A., Milligan, P.E., Grosso, L., Eby, C., Deych, E., Grice, G., Clohisy, J.C., Barrack, R.L., Burnett, R.S., Voora, D., Gatchel, S., Tiemeier, A. & Gage, B.F. (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood, 110, 15111515.
  • Oates, A., Jackson, P.R., Austin, C.A. & Channer, K.S. (1998) A new regimen for starting warfarin therapy in out-patients. British Journal of Clinical Pharmacology, 46, 157161.
  • Oldenburg, J., Bevans, C.G., Fregin, A., Geisen, C., Muller-Reible, C. & Watzka, M. (2007a) Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thrombosis and Haemostasis, 98, 570578.
  • Oldenburg, J., Watzka, M., Rost, S. & Muller, C.R. (2007b) VKORC1: molecular target of coumarins. Journal of Thrombosis and Haemostasis, 5(Suppl 1), 16.
  • Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., Devoto, G., Berrettini, M. & Musolesi, S. (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet, 348, 423428.
  • Rieder, M.J., Reiner, A.P., Gage, B.F., Nickerson, D.A., Eby, C.S., McLeod, H.L., Blough, D.K., Thummel, K.E., Veenstra, D.L. & Rettie, A.E. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New England Journal of Medicine, 352, 22852293.
  • Roberts, G.W., Druskeit, T., Jorgensen, L.E., Wing, L.M., Gallus, A.S., Miller, C., Cosh, D. & Eaton, V.S. (1999) Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Australia and New Zealand Journal of Medicine, 29, 731736.
  • Rosove, M.H. & Grody, W.W. (2009) Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Annals of Internal Medicine, 151, 270273, W95.
  • Schulman, S. & Kearon, C. (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis, 3, 692694.
  • Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L., King, B.P., Wood, P., Kesteven, P., Daly, A.K. & Kamali, F. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 106, 23292333.
  • Tait, R.C. & Sefcick, A. (1998) A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation. British Journal of Haematology, 101, 450454.
  • Thacker, S.M., Grice, G.R., Milligan, P.E. & Gage, B.F. (2008) Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes. Journal of Thrombosis and Haemostasis, 6, 14451449.
  • Voora, D., Eby, C., Linder, M.W., Milligan, P.E., Bukaveckas, B.L., McLeod, H.L., Maloney, W., Clohisy, J., Burnett, R.S., Grosso, L., Gatchel, S.K. & Gage, B.F. (2005) Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thrombosis and Haemostasis, 93, 700705.
  • Wadelius, M., Chen, L.Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D. & Deloukas, P. (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. The Pharmacogenomics Journal, 5, 262270.
  • Yuan, H.Y., Chen, J.J., Lee, M.T., Wung, J.C., Chen, Y.F., Charng, M.J., Lu, M.J., Hung, C.R., Wei, C.Y., Chen, C.H., Wu, J.Y. & Chen, Y.T. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human Molecular Genetics, 14, 17451751.